Publicaciones en las que colabora con Josep Tabernero Caturla (18)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  2. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

2023

  1. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

    Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229

2021

  1. A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors

    Radiology, Vol. 299, Núm. 1, pp. 109-119

  2. Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

    ESMO Open

  3. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials

    European Journal of Cancer, Vol. 155, pp. 168-178

2020

  1. Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria

    Clinical Cancer Research, Vol. 26, Núm. 8, pp. 1846-1855

  2. Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas

    Clinical Cancer Research, Vol. 26, Núm. 4, pp. 902-909

  3. Identification of expression profiles defining distinct prognostic subsets of radioactive-iodine refractory differentiated thyroid cancer from the DECISION trial

    Molecular Cancer Therapeutics, Vol. 19, Núm. 1, pp. 312-317

2019

  1. Early evolutionary divergence between papillary and anaplastic thyroid cancers

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, Núm. 11, pp. 1843

  2. Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials

    Expert Opinion on Investigational Drugs, Vol. 28, Núm. 5, pp. 463-471

2018

  1. Early evolutionary divergence between papillary and anaplastic thyroid cancers

    Annals of Oncology, Vol. 29, Núm. 6, pp. 1454-1460

  2. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer

    Expert Opinion on Pharmacotherapy, Vol. 19, Núm. 6, pp. 623-629

  3. The safety of ramucirumab for the treatment of colorectal cancer

    Expert Opinion on Drug Safety, Vol. 17, Núm. 9, pp. 945-951

2017

  1. Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights

    Molecular Oncology, Vol. 11, Núm. 9, pp. 1263-1272

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer

    Expert Opinion on Emerging Drugs, Vol. 21, Núm. 3, pp. 267-282

2010

  1. Treatment of cancer with oral drugs: A position statement by the Spanish Society of Medical Oncology (SEOM)

    Annals of Oncology